Search Results - Jasper Dingemanse

Drug Development for Pediatric Populations: Regulatory Aspects by Jochen Zisowsky, Jasper Dingemanse, Andreas Krause

Connect to this object online.

Clinical Pharmacology of Clazosentan, a Selective Endothelin A Receptor Antagonist for the Prevention and Treatment of aSAH-Related Cerebral Vasospasm by Pierre-Eric Juif, Jasper Dingemanse, Mike Ufer

Connect to this object online.

Pharmacokinetics of daridorexant, a dual orexin receptor antagonist, are not affected by renal impairment by Benjamin Berger, Clemens Muehlan, Gernot Klein, Jasper Dingemanse

Connect to this object online.

Pharmacokinetics and Pharmacodynamics of Cenerimod, A Selective S1P1R Modulator, Are Not Affected by Ethnicity in Healthy Asian and White Subjects by Pierre‐Eric Juif, Jasper Dingemanse, Peter Winkle, Mike Ufer

Connect to this object online.

Pharmacokinetic/pharmacodynamic modeling of drug interactions at the P2Y12 receptor between selatogrel and oral P2Y12 antagonists by Andrea Henrich, Christian Hove Claussen, Jasper Dingemanse, Andreas Krause

Connect to this object online.

Effect of Daridorexant on the Pharmacokinetics of Midazolam, and on the Pharmacokinetics and Pharmacodynamics of Warfarin in Healthy Male Subjects by Isabelle Zenklusen, Jasper Dingemanse, Christian Reh, Martine Gehin, Priska Kaufmann

Connect to this object online.

Population pharmacokinetic modeling of daridorexant, a novel dual orexin receptor antagonist by Andreas Krause, Dominik Lott, Janneke M. Brussee, Clemens Muehlan, Jasper Dingemanse

Connect to this object online.

Influence of Rifampin‐Mediated Organic Anion‐Transporting Polypeptide 1B1/1B3 Inhibition on the Pharmacokinetics of Clazosentan by Pierre‐Eric Juif, Christine Voors‐Pette, Mike Ufer, Peter Dogterom, Jasper Dingemanse

Connect to this object online.

Effect of nivasorexant (ACT‐539313), a selective orexin‐1‐receptor antagonist, on multiple cytochrome P450 probe substrates in vitro and in vivo using a cocktail approach in health... by Benjamin Berger, Priska Kaufmann, Matthias Berse, Alexander Treiber, Nathalie Grignaschi, Jasper Dingemanse

Connect to this object online.

Effect of Rifampin‐Mediated OATP1B1 and OATP1B3 Transporter Inhibition on the Pharmacokinetics of the P2Y12 Receptor Antagonist Selatogrel by Uta Schilling, Jasper Dingemanse, Christine Voors‐Pette, Christel Romeijn, Peter Dogterom, Mike Ufer

Connect to this object online.

Assessment of Target Engagement in a First‐in‐Human Trial with Sinbaglustat, an Iminosugar to Treat Lysosomal Storage Disorders by Martine Gehin, Meggane Melchior, Richard W.D. Welford, Patricia N. Sidharta, Jasper Dingemanse

Connect to this object online.

The effect of itraconazole, a strong CYP3A4 inhibitor, on the pharmacokinetics of the first‐in‐class ACKR3/CXCR7 antagonist, ACT‐1004‐1239 by Christine Huynh, Jasper Dingemanse, Henriette E. Meyer zu Schwabedissen, Marlene Fonseca, Patricia N. Sidharta

Connect to this object online.

Influence of hepatic impairment on the pharmacokinetics and pharmacodynamics of the P2Y12 receptor antagonist selatogrel by Uta Schilling, Chih‐Hsuan Hsin, Stephane Delahaye, Andreas Krause, Hauke Wuelfrath, Atef Halabi, Jasper Dingemanse

Connect to this object online.

Evaluation of the cytochrome P450 2C19 and 3A4 inhibition potential of the complement factor 5a receptor 1 antagonist ACT‐1014‐6470 in vitro and in vivo by Marion Anliker‐Ort, Jasper Dingemanse, Stephane Delahaye, Luboš Janů, John van denAnker, Benjamin Berger, Priska Kaufmann

Connect to this object online.

Modeling time‐delayed concentration‐QT effects with ACT‐1014‐6470, a novel oral complement factor 5a receptor 1 (C5a1 receptor) antagonist by Marion Anliker‐Ort, Chih‐hsuan Hsin, Andreas Krause, Marc Pfister, John van denAnker, Jasper Dingemanse, Priska Kaufmann

Connect to this object online.

Absorption, Metabolism, and Excretion of ACT-1004-1239, a First-In-Class CXCR7 Antagonist: In Vitro, Preclinical, and Clinical Data by Christine Huynh, Christine Huynh, Swen Seeland, Jerome Segrestaa, Carmela Gnerre, Jens Hogeback, Henriette E. Meyer zu Schwabedissen, Jasper Dingemanse, Patricia N. Sidharta

Connect to this object online.

The interactive walkway provides fit‐for‐purpose fall‐risk biomarkers in the elderly: Comparison of zolpidem and suvorexant by Ingrid Koopmans, Daphne Geerse, Lara deRidder, Melvyn Roerdink, Maria Joanna Juachon, Clemens Muehlan, Jasper Dingemanse, Joop vanGerven, Geert Jan Groeneveld, Rob Zuiker

Connect to this object online.

Quantification of increased biologically active CXCL12α plasma concentrations after ACKR3 antagonist treatment in humans by Peter Blattmann, Hervé Farine, Brian Dan, Nicole Stiffler, Thomas Lefebvre, Christine Huynh, Patricia N. Sidharta, Jasper Dingemanse, Richard W. D. Welford, Marcel Keller, Daniel S. Strasser

Connect to this object online.